TP53 and non-small cell lung carcinoma: To date, in advanced EGFR‐mutated NSCLC, co‐occurring mutations and/or amplifications in the tumor protein p53 (TP53), HER2, MET, CDK4/6 gene, etc., have been reported to negatively affect the survival outcome of the patients treated with EGFR‐TKIs [15, 16, 17, 18, 19, 20, 21, 22, 23].